Key result
Vasopressin serves as a potential adjunct vasopressor in the treatment of cardiac arrest and severe shock states unresponsive to conventional catecholamine therapy.
Vasopressin is a valuable adjunctive therapy in critical care and anesthesia for managing refractory vasodilatory shock and cardiac arrest.
Answers are grounded in this paper and cite their sources.
May support adjunctive use in refractory shock; leaves open need for RCTs to guide practice.
Vasopressin or antidiuretic hormone is a potent endogenous hormone, which is responsible for regulating plasma osmolality and volume. In high concentrations, it also raises blood pressure by inducing moderate vasoconstriction. It acts as a neurotransmitter in the brain to control circadian rhythm, thermoregulation and adrenocorticotropic hormone release. The therapeutic use of vasopressin has become increasingly important in the critical care environment in the management of cranial diabetes insipidus, bleeding abnormalities, esophageal variceal hemorrhage, asystolic cardiac arrest and septic shock. After 10 years of ongoing research, vasopressin has grown to a potential component as a vasopressor agent of the anesthesiologist's armamentarium in the treatment of cardiac arrest and severe shock states.
No takes yet. Share an insight, caveat, or question.
Sengupta et al. (2011) conducted a review in Shock states and cardiac arrest. Vasopressin was evaluated. Vasopressin serves as a potential adjunct vasopressor in the treatment of cardiac arrest and severe shock states unresponsive to conventional catecholamine therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: